Nexa Resources S.A. NEXA 深 滬
已收盤 12-24 16:00:00 美东时间
8.85
-0.050
-0.56%
華盛通- 最 高9.05
- 今 開9.00
- 成交量 28.16万股
- 最 低 8.78
- 昨 收 8.90
- 總市值 11.68亿
- 52周最高 9.4591
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 4.438
- 委 比 50.00%
- 總股本 1.32亿
- 歷史最高 19.1752
- 量 比 0.32
- 振 幅 3.03%
- 歷史最低 1.6333
- 每 手 1
- 風險率 0.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Silver tops all-time high of $70/oz and these mining companies have taken notice
Silver mining stocks surged as the precious metal (XAGUSD:CUR) topped $70 per ounce for the first time, sparking renewed investor interest in the sector. In response, Seeking Alpha highlighted mining ...
12-24 00:37
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Nexa Res Q3 Adj. EPS $(0.03) Misses $0.07 Estimate, Sales $763.515M Beat $702.979M Estimate
Nexa Res (NYSE:NEXA) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.07 by 140 percent. This is a 250 percent decrease over earnings of $0.02 per share from the same
10-31 04:48
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
Scotiabank Maintains Sector Perform on Nexa Res, Raises Price Target to $6
Scotiabank analyst Orest Wowkodaw maintains Nexa Res (NYSE:NEXA) with a Sector Perform and raises the price target from $5.5 to $6.
10-29 00:54
Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
Three independent studies published in *Alzheimer's Research & Therapy*, *Journal of Alzheimer's Disease*, and *Radiology* validate Nexalin's non-invasive DIFS™ technology, demonstrating significant cognitive and neuroimaging benefits in Alzheimer's patients. The studies highlight improvements in memory, brain connectivity, and network功能, positioning Nexalin as a potentially paradigm-shifting, drug-free solution with fewer risks and costs compare...
10-21 13:00
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
10-14 20:00
